NASDAQ
Entrada Therapeutics, Inc. (TRDA)
♥ 552 Thanks from members
Entrada Therapeutics, Inc. (TRDA) displays a neutral-to-cautious market sentiment driven by narrowing quarterly losses, a $223 million cash runway into Q3 2027, and an upcoming dense schedule of Phase 1/2 clinical readouts across its DMD and DM1 franchises.